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ABSTRACT    
The Indian pharmaceutical industry has experienced rapid growth, becoming the world’s largest 
provider of generic drugs, based on product and process innovation. The industry has undergone 
dynamic changes in recent decades, operating in a rapidly evolving environment affected by 
domestic and global policies; a key example of the latter is the TRIPS agreement. Taking an 
intellectual property perspective, we describe how changes in the innovation ecosystem have 
affected companies’ strategies related to international activity and accessing knowledge from 
both internal and external knowledge sources, during the transitional- and post-TRIPS periods 
(1995-2004 and 2005-2014, respectively). Combining intellectual property arguments with 
contextual aspects of the innovation ecosystem, we conjecture that, in the post-TRIPS period, 
externally-sourced knowledge will be more important than internally-sourced knowledge, for 
Indian pharmaceutical firms’ international business activity.  
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pharmaceutical industry, international business
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INTRODUCTION 
Recent research has placed considerable emphasis on emerging-market firms and the impact of 
institutional context on their strategic choices (Chari & David, 2012; Chittoor, Kale, & Puranam, 
2015; Cuervo-Cazurra & Dau, 2009). Many such firms have transformed themselves to be 
globally competitive, responding to institutional transitions and the resulting ecosystem changes 
in their home markets over recent decades (Cuervo-Cazurra & Genc, 2008; Ramamurti, 2012a). 
Because innovations are embedded in institutional contexts, the country-specific triggers and 
drivers of innovation processes are important (Chittoor, Aulakh, & Ray, 2015; Peng, Ahlstrom, 
Carraher, & Shi, 2017; Thakur-Wernz & Samant, 2017). The strength of the intellectual property 
(IP) regime is one such trigger, playing a key role in driving innovation in knowledge-intensive 
industries such as pharmaceuticals (Brandl, Darendeli, & Mudambi, 2018; Kale & Wield, 2008; 
Papageorgiadis & McDonald, 2019). The high costs of developing drugs, combined with the 
presence of stringent regulations, makes IP rights particularly important in this sector, in terms of 
the appropriation of monopoly rents by inventors (Kale, 2010; Pisano, 2006; Teece, 1986).  
In recent decades, greater levels of liberalization and globalization have encouraged rapid 
internationalization by emerging-market firms (Ramamurti, 2012b). With home markets 
characterized by institutional voids (Khanna & Palepu, 2000), resource constraints, and 
tendencies toward risk-aversion (Courtney, Kirkland, & Viguerie, 1997), many emerging-market 
firms have used catching up with advanced-economy competitors as a key motivation for their 
internationalization (e.g., Awate, Larsen, & Mudambi, 2015). In this regard, the knowledge-
seeking motive is critically important; the literature generally suggests that this is more 
consistent with high-commitment internationalization, such as foreign direct investment (FDI), 
than lower-commitment and lower-risk approaches (e.g., exporting). However, the home context 
3 
 
 
 
plays a role in entry mode choices. There is evidence that typologies describing a progression 
from lower- to higher-commitment entry modes (e.g., Buckley & Casson, 1998; Johanson & 
Vahlne, 1977) apply to emerging-market firms’ internationalization into other emerging or 
developing economies, which is driven more by market- or resource-seeking than a search for 
knowledge to transfer back home. However, the situation is different when emerging-market 
firms target advanced economies. In this situation, exporting may be a key strategy for market-
seeking, while knowledge-seeking is the primary motivation behind FDI.4  
The Indian pharmaceutical industry offers a prime example of this dichotomy, with 
exports, to both emerging and developed markets (Chittoor, Ray, Aulakh, & Sarkar, 2008), 
contributing over 50% of its total revenues. Though knowledge resources are recognized as key 
export drivers for innovation-driven pharmaceutical firms (Chittoor, Sarkar, Ray, & Aulakh, 
2009), less is understood about the nature of the knowledge-performance relationship in the face 
of a changing IP regime (Chatterjee & Sahasranamam, 2018; Nair, Guldiken, Fainshmidt, & 
Pezeshkan, 2015). India offers a useful environment for considering how a drastically-altered 
innovation system affects companies’ knowledge sourcing strategies and, in turn, their 
international business activities.   
The adoption of TRIPS5 in developing countries has varied over time, often depending on 
the roles played by global actors (Brandl et al., 2018). In the Indian context, it is useful to 
consider two distinct periods of TRIPS adoption – transitional-TRIPS (1995-2004) and post-
TRIPS (2005-2014) – to understand the impact of IP changes on knowledge sourcing strategies. 
With non-equity-based modes6, firms can source knowledge either internally, through investment 
                                                 
4 We are grateful to Ram Mudambi for raising this line of reasoning. 
5 Trade Related Intellectual Property Rights 
6 Other sources that firms use for obtaining knowledge include cluster spillovers and equity-based modes such as 
acquisitions and joint ventures. 
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in research and development (Kumar & Aggarwal, 2005), or from external resources through 
licenses, trade agreements, or blueprints against a royalty fee (Bhat & Narayanan, 2009; Lane & 
Probert, 2007). In high-technology industries such as pharmaceuticals, firms tend to focus on 
developing technology internally in areas in which they have key strengths, and source other 
technology externally (Dunlap, McDonough, Mudambi, & Swift, 2016). While the distinction 
between internal and external knowledge has been addressed in the innovation literature (e.g. 
Casillas, Moreno, Acedo, Gallego, & Ramos, 2009), less is understood about the roles of internal 
and external knowledge sources in driving international business activity (Denicolai, Zucchella, 
& Strange, 2014; Wang, Cao, Zhou, & Ning, 2013). Research has suggested that internal R&D 
and external knowledge acquisition represent complementary innovation strategies, but that the 
complementarity is sensitive to the institutional environment (Cassiman & Veugelers, 2006). The 
TRIPS-induced IP reforms created fundamental changes in the institutional environment for 
India’s pharmaceutical industry, forcing domestic firms to reconfigure their knowledge resources 
and capabilities, and to acquire new capabilities (Brandl et al., 2018; Chittoor & Ray, 2007; 
Chittoor et al., 2009). Against this background, using the perspective of IP (Pisano, 2006; Teece, 
1986), we discuss how changes in the IP regime influenced firms’ strategies related to internal 
and external knowledge sources, and speculate about the subsequent impact on their international 
business activities.  
Many Indian industries, including pharmaceuticals, experienced an exogenous shock 
when India became a signatory to the World Trade Organization (WTO) on 1st January 1995. 
Given a transition period of 10 years to amend its patent laws, India moved from an era of 
process patents to honoring product patents starting from 1st January 20057. Now that over a 
                                                 
7 An example of a similar pharmaceutical process patent regime can be found in 19th century Germany (Murmann, 
2003).  
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decade has passed since the new patent regulations have taken effect, we are able to consider 
how IP reforms influence knowledge sourcing, by comparing the transitional- and post-TRIPS 
periods.  
In this paper, we contribute to the literatures on innovation and intellectual property in 
several ways. First, we use IP frameworks to illuminate the role of knowledge sources in firms’ 
international business activity during a period of regulatory transition. Specifically, we, extend 
the understanding of the impact of institutional context, by focusing on the effect of IP reforms 
on emerging-market firms (Chittoor & Ray, 2007; Chittoor et al., 2008; Kale & Little, 2007; 
Kale & Wield, 2008), addressing how knowledge sourcing strategies differ under different 
institutional environments. Considering the historical institutional context of the innovation 
ecosystem, we conjecture that internal knowledge sourcing strategies are less important for the 
international business activities of Indian pharmaceutical firms in the post-TRIPS period. 
However, the strong patent systems in the post-TRIPS period mean that external knowledge 
sourcing is likely to be influential. Second, we provide insights into the complementary aspects 
of internal and external knowledge sourcing, and the associated role of the innovation ecosystem 
(Bilgili, Kedia, & Bilgili, 2016; Cassiman & Veugelers, 2006); in the face of a changing 
innovation ecosystem, we conjecture that Indian pharmaceutical firms draw more from external 
knowledge sourcing opportunities, to complement historical weaknesses in their internal 
knowledge sourcing. Finally, we add to the understanding of innovation management in the 
Indian context, which has received limited attention in prior literature (Chatterjee & 
Sahasranamam, 2018; Nair et al., 2015). Specifically, we highlight the evolution of the Indian 
pharmaceutical industry in the face of multiple changes in the innovation ecosystem since 1947, 
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especially the exogenous shock created by TRIPS, and how this history shapes firms’ knowledge 
sourcing strategies associated with their international business activity. 
EVOLUTION OF THE INDIAN PHARMACEUTICAL INDUSTRY AND KEY 
INSTITUTIONAL CHANGES 
The evolution of the Indian pharmaceutical industry in the post-independence period, and the 
ensuing institutional changes, can be divided into three phases (Chaturvedi, Chataway, & Wield, 
2007). The first phase (1947-1970) corresponds to the regulations according to the Patents and 
Designs Act of 1911, which was a holdover from the pre-independence period of British rule. 
This patent regime provided protection for all inventions, apart from those related to atomic 
energy, offering exclusive rights for a period of 16 years from the date of application (Pradhan, 
2007). The regime is viewed as having had a negative effect on the growth of the domestic 
pharmaceutical industry, resulting in high drug prices (Mohammad & Kamaiah, 2014), leading 
to domestic pressure to move to a less restrictive patent regime (Desai, 1980).  
The second phase (1970-1995) covers the period after India introduced its own Patents 
Act in 1970, which was operational until the country became a signatory to the WTO on 1st 
January 1995. During this phase, product patents were offered for most inventions; exceptions 
were food, medicine, drugs, and substances produced by chemical processes, for which only 
process patents were available (Pradhan, 2007). This change in the innovation ecosystem led to 
rapid growth in the Indian pharmaceutical industry, boosting local innovation in the form of 
adaptation and reverse engineering. The number of Indian pharmaceutical firms grew from 2,257 
in 1970 to over 23,000 by 2005 (Haley & Haley, 2012); by the 2000s, domestic pharmaceutical 
companies enjoyed a market share of 60-70%, compared to 10% during the 1970s (Kale, 2010). 
To the benefit of domestic firms, foreign pharmaceutical multinationals in India were 
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disadvantaged on two counts. First, the weak product patent regime offered foreign firms little 
incentive to market their patented products. Second, they were losing market share to price-
competitive Indian firms in global markets, due to the patent regime that allowed Indian firms to 
reverse engineer drugs’ chemical molecules (Chittoor et al., 2009).  
This pre-TRIPS period also witnessed a stark fragmentation of the pharmaceutical 
industry, between Indian firms and foreign multinationals, based on their divergent views on the 
trade regime. In particular, the Indian firms generally perceived the TRIPS agreement as a threat 
to their continued success. This fragmentation led to the rise of  two industry associations (Sinha, 
2016). The Indian Drug Manufacturers Association (IDMA) had been formed in 1961 to 
represent the interests of domestic firms (including Ranbaxy and Cipla) to the Indian 
government. Foreign and multinational companies had established the other association – the 
Organization of the Pharmaceutical Producers from India (OPPI) – in 1965. By the late 1990s, 
the interests of eight large, research-oriented Indian companies, which had developed a more 
positive view on the TRIPS patent regime (Sinha, 2016), diverged from the views of the IDMA, 
leading to the formation of a separate coalition – the Indian Pharmaceutical Alliance (IPA) – to 
interact with the government. Still, the clearly-divergent interests of domestic firms and foreign 
subsidiaries meant that there was little knowledge spillover between them during this pre-TRIPS 
period (Brandl, Mudambi, & Scalera, 2015).  
The third phase began in 1995. In the pre-TRIPS era, the Indian pharmaceutical industry 
was supported by favorable government policies and soft patent regimes. When India joined the 
WTO and became a signatory of TRIPS, Indian pharmaceutical firms were forced to make the 
transition from protection under process patents to protection based on product patents (Chittoor 
et al., 2009). The introduction of product patents was expected to have a negative impact on the 
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Indian pharmaceutical industry, blocking the Indian firms’ main source of chemical molecules 
(Watal & Mathai, 1995). Under the process patent regime, Indian firms had been free to reverse-
engineer new technologies or molecules without formal licenses from patent holders (Kale & 
Wield, 2008). As the TRIPS era came closer, during 1994-1995, multiple camps arose within the 
domestic pharmaceutical industry, comprising some in favor of the regime change, some who 
wanted to oppose it at any cost, and some in denial of its potential impact (Sinha, 2016). The 
broad consensus view was, however, that TRIPS was essentially a necessary evil (Sinha, 2016).    
The transitional-TRIPS period of 1995-2004 saw the changeover from process to product 
patents, through a series of three legislative amendments. In 1999, the Indian government 
enacted a patent-reform amendment to the Patents Act of 1970. Retroactive to 1995, this 
amendment provided for a “mailbox system” of patent applications, enabling firms to file patents 
for future approval. This allowed companies to file for patents that would be approved upon 
implementation of the product-patent regime in 2005 (Haley & Haley, 2012). A second 
amendment was enacted in 2002, extending the patent duration to 20 years for existing and 
pending applications. The third amendment came into effect from April 2005, providing for 
product patent protection for pharmaceuticals (Pradhan, 2007). 
Despite the radical change in the IP regime and the necessary transformations in the 
innovation ecosystem, the Indian pharmaceutical industry’s revenues – both domestic and from 
exports – continued to grow. By 2013, it had become the world’s third-largest, in terms of value 
(Horner, 2014), partly attributable to the evolution of firms’ dynamic capabilities as strategic 
responses to the regulatory changes (Athreye, Kale, & Ramani, 2009). Manufacturers of generic 
drugs remained the dominant players in the industry, with patented drugs accounting for only 1% 
of India’s pharmaceutical market (Kochhar, 2014).  
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Exports played – and continue to play – a key role in the Indian pharmaceutical industry, 
contributing over 50% of its total revenues in 2013, and the industry’s balance of trade changed 
dramatically during 2005-2014, as shown in Figure 1.  
------------------------------------------------ 
Insert Figure 1 about here 
------------------------------------------------ 
 
The post-TRIPS period has seen greater investment in R&D (Jagadeesh & Sasidharan, 
2014; Chittoor et al., 2009), which has led to product patents related to new dosage forms and an 
increased focus on new drug discovery (Agarwal, Gupta, & Dayal, 2007; Basant & Srinivasan, 
2015). The government-run Council of Scientific and Industrial Research (CSIR) has played a 
crucial role in this regard; CSIR was responsible for gaining 540 new U.S. patents during 1995-
2015, compared with 27 between 1950 and 1993 (Brandl et al., 2015). Many domestic firms 
followed the government’s lead by investing more resources into R&D. With the largest number 
of USFDA-approved manufacturing plants outside of the U.S. (Balakrishnan, 2014), the Indian 
pharmaceutical industry experienced improvements that enabled it to target lucrative western 
markets via exporting.  
The change in the nature of the patents, from process to product, makes it important to 
study the transitional-TRIPS (1995-2004) and post-TRIPS (2005-2014) periods separately 
(Brandl et al., 2018). Thus, we consider the two timeframes, and explore the effect of IP reform 
on the relationship between knowledge sources and international business activities in the 
context of the Indian pharmaceutical industry. 
THEORY AND LITERATURE REVIEW 
Innovation Ecosystems, Intellectual Property Rights and Emerging Markets 
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A focus on institutions and ecosystems has been a dominant feature of innovation and 
entrepreneurship research in India (Chatterjee & Sahasranamam, 2014; Sahasranamam & Ball, 
2018; Schøtt, Madhavan, Jensen, & Li, 2019). The innovation ecosystems view incorporates 
private firms and public organizations, and investigates their mutual interactions as well as their 
relationships with the social and institutional framework in which they are embedded (Lundvall, 
1999).  
A key issue in research involving innovation ecosystems pertains to how the selection of 
a particular appropriation mechanism influences the distribution of value across innovating 
firms, rivals, consumers, and suppliers (Papageorgiadis & McDonald, 2019). Teece (1986: 287) 
acknowledges the need for strong appropriability for capturing value from innovations, noting 
that the “regime of appropriability refers to the environmental factors, excluding firm and market 
structure, that govern an innovator’s ability to capture the profits generated by an innovation”. In 
the absence of such protection, imitation is relatively easy, and the profits from innovation tend 
to accrue to the owners of key complementary assets, rather than the innovator.  
The efficacy of IP protection varies across contexts (Papageorgiadis, Cross, & Alexiou, 
2014; Papageorgiadis & McDonald, 2019), and the value capture literature discusses legal 
protection as a critical context-dependent institutional factor (Lanjouw & Schankerman, 2001; 
Sahasranamam & Nandakumar, 2018). The strength of the legal protection regime affects the 
cost of imitation; weak regimes, with lower penalties, are characterized by greater likelihood of 
patent infringement (Papageorgiadis, Cross, & Alexiou, 2013; Papageorgiadis et al., 2014). 
Strong appropriability regimes allow firms to identify, and defend against, infringement 
(Lanjouw & Schankerman, 2004). In countries with weaker appropriability regimes, including 
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many emerging markets, firms face greater difficulty in defending against infringement (Krug & 
Hendrischke, 2003; Sahasranamam & Raman, 2018).   
 
KNOWLEDGE SOURCING AND INTERNATIONAL BUSINESS ACTIVITY 
For firms from emerging markets, including India, internationalization is a particularly risky 
strategy, considering the extent of resource investment needed and the firms’ often-limited prior 
experience with competing in global markets (Contractor, Kumar, & Kundu, 2007; Luo & Tung, 
2007). Until economic liberalization in 1991, the heavily-regulated home market did not 
encourage Indian firms to explore foreign options, and the large domestic population meant that 
international expansion was not an imperative (Kumaraswamy, Mudambi, Saranga, & Tripathy, 
2012). However, post-1991, Indian firms have internationalized and become globally 
competitive. Consistent with the literature (e.g., Agnihotri & Bhattacharya, 2015; Buckley & 
Casson, 1998; Johanson & Vahlne, 1977), exporting is often the initial internationalization 
strategy for Indian firms, and remains key today. 
 Access to knowledge is essential for enhancing product quality, identifying new 
opportunities, and increasing competitiveness (Grant, 1996; Zhou & Li, 2012). In the absence of 
equity-based relationships, knowledge acquisition is most likely to occur through internal 
mechanisms, such as R&D, or externally through royalties and licenses. The TRIPS regime gave 
greater protection to inventors, leading to a two-pronged reaction by Indian firms: (1) 
augmenting their own research capabilities in order to transition from core process research to 
new drug development, and (2) sourcing external knowledge by forging commercial alliances 
with global companies (Khan & Nasim, 2016).  
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Table 1 presents a summary of key quantitative studies of the relationship between 
exporting and both internal and external knowledge sourcing in the Indian context. While the 
results are mixed, and reflect little research pertaining to the post-TRIPS period, there is some 
evidence of the impact of TRIPS, especially on the relationship between R&D and exporting.8 
This suggests that a more nuanced consideration of different periods in the TRIPS adoption 
process – e.g., transitional-TRIPS and post-TRIPS – is necessary to explore how changes in the 
IP regime may affect the relationship between knowledge sourcing and international activity.   
---------------------------------------------- 
Insert Table 1 about here 
---------------------------------------------- 
 
Internal knowledge sourcing  
R&D investment levels provide a broad indication of the priority that firms give to developing 
new products using internal sources of knowledge (Kumar & Siddharthan, 1994; Lall & Kumar, 
1981). High R&D investment suggests a focus on internal exploration for developing new 
products and/or markets (Chittoor & Ray, 2007), and has been identified as influential for 
gaining market share and helping firms to be more globally competitive (Boso, Story, Cadogan, 
Micevski, & Kadic-Maglajlic, 2013).  
It is reasonable to assume that the relationship between R&D and international business 
activity –export intensity in particular, for the Indian pharmaceutical industry – evolves under a 
changing IP regime. Pharmaceutical firms face a protracted process of moving from drug 
discovery to commercialization, and very expensive R&D makes IP protection crucial for 
knowledge ownership (Kale & Wield, 2008). However, the impact of IP protection on the 
relationship between R&D investment and export intensity in high-technology Indian industries 
                                                 
8 Note that considering effect sizes tempers the interpretations. 
13 
 
 
 
is complex. On one hand, considering the expropriation protection argument (Teece, 1986), the 
stronger IP protection post-TRIPS might incentivize R&D investment, leading to improved 
international performance. In addition, greater competition from foreign MNEs in a stronger IP 
regime (Hu, 2010) may make domestic firms upgrade their internal knowledge capabilities 
through R&D, to survive and then compete globally (Chatterjee & Sahasranamam, 2018; 
Kumaraswamy et al., 2012). Such increased R&D investment helps to translate resources into 
innovative products, which may give firms temporary monopoly positions (Roberts, 2001) or 
reduce entry barriers (Harris & Li, 2009), enabling them to capture new opportunities in 
international markets (Hasan & Raturi, 2003).  
On the other hand, the Indian pharmaceutical industry’s focus on generic drugs may 
mean that firms struggle to benefit from increased investment in R&D, at least in the short term; 
the capabilities associated with generic drugs are not necessarily useful for developing higher-
value, breakthrough drugs (Dunlap-Hinkler, Kotabe, & Mudambi, 2010). Translating R&D 
investment into innovation requires both substantial expertise in therapeutic areas and strong 
communication across disciplines. However, the traditional specialization of Indian 
pharmaceutical firms – generic drugs based on reverse engineering (Haley & Haley, 2012) – is 
based on different types of expertise, lower cost, and less extensive need for cross-disciplinary 
interaction (Henderson, Orsenigo, & Pisano, 1999). The Indian firms’ more limited prior 
experience with developing new molecules may delay the translation of R&D investments into 
new drug formulations, competitive advantage, and export intensity (Tyagi, Mahajan, & 
Nauriyal, 2014). Given these short-term disadvantages related to developing capabilities 
associated with the new focus on product-related patent protection, we propose: 
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Proposition 1: Among Indian pharmaceutical firms, the relationship between internal 
knowledge sources and international business activity is weaker post-TRIPS than in the 
transitional-TRIPS period. 
 
External knowledge sourcing  
With the TRIPS agreement changing the nature of the IP regime, Indian pharmaceutical firms 
began to forge commercial alliances with foreign inventors, aimed at sourcing knowledge (Khan 
& Nasim, 2016). India’s emerging-market status and the technological nature of the industry 
made external knowledge sourcing particularly important for international competitiveness for 
several reasons. First, technology accessed solely from within an emerging-market firm, or from 
domestic sources, may be insufficient to support international success in a rapidly-changing 
technological environment (Chatterjee & Sahasranamam, 2018; Li, Chen, & Shapiro, 2010). 
Hence, firms seek external knowledge for developing new innovations (Awate et al., 2015; 
Thakur-Wernz & Samant, 2017). Second, because new inventions emerge from a recombinative 
process using different streams of knowledge (Fleming, 2001), external sources are especially 
valuable for helping emerging-market firms to develop internationally-exploitable innovations 
(Wang et al., 2013). Third, external knowledge sourcing offers opportunities for close interaction 
with foreign partners, enabling emerging-market firms to develop deeper insights into the nature 
of international markets and build a valuable network of foreign contacts. As emerging-market 
firms tend to be later internationalizers, these benefits are crucial for increasing export intensity 
(Gaur & Kumar, 2010; Singh & Gaur, 2013). Finally, external knowledge acquisition can 
accelerate firms’ innovation processes, facilitating catch-up in both domestic and international 
markets (Awate, Larsen, & Mudambi, 2012; Kumaraswamy et al., 2012). 
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In the absence of effective patent protection (e.g., during the pre- and transitional-TRIPS 
periods), fear of imitation impedes external knowledge sourcing (Kale, 2010). Foreign firms with 
the potential to offer external knowledge support may be reluctant to share their proprietary 
know-how, due to concern about reverse engineering of their licensed technologies (Horner, 
2014). However, stronger patent protection (e.g., in the post-TRIPS period) should promote 
technological development by encouraging the acquisition of knowledge through market 
mechanisms such as technology licensing and royalty agreements (Arora, Fosfuri, & Rønde, 
2013; Smith, 2001). Advanced-economy universities and research institutions may also be 
valuable sources of external knowledge for emerging-market firms (Perri, Scalera, & Mudambi, 
2017), with knowledge transfer facilitated by stronger IP regimes (Papageorgiadis et al., 2013). 
Considering the increased importance of external knowledge sources, and the more conducive 
conditions for sourcing knowledge in an enhanced IP regime, we propose:  
Proposition 2: Among Indian pharmaceutical firms, the relationship between external 
knowledge sources and international business activity is stronger post-TRIPS than in the 
transitional-TRIPS period. 
DISCUSSION AND IMPLICATIONS  
The IP reforms initiated in 1995 changed the Indian pharmaceutical industry’s innovation 
ecosystem substantially (Bouet, 2015; Chittoor & Ray, 2007; Chittoor et al., 2009). We argue 
that understanding the impact of this change requires distinguishing between internal and 
external sources of knowledge (Cassiman & Veugelers, 2006), and their relative importance for 
firms’ international activities, in the distinct IP regimes of the transitional-TRIPS and post-
TRIPS periods. Kale & Wield (2008) concluded that Indian pharmaceutical firms adopted an 
ambidextrous capability development approach (O’Reilly III & Tushman, 2011), involving both 
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exploitation and exploration, to adapt to the post-1995 IP environment. This entailed entering 
advanced markets (U.S. and Europe), exploiting existing process-related R&D skills, and 
investing in explorative capability development for R&D aimed at innovation. Bouet (2015) 
found that, while necessary for innovation, TRIPS compliance is not sufficient for increasing the 
value of exports. We suggest that Indian pharmaceutical firms’ explorative capabilities may be 
more dependent on the market for external knowledge that was created by TRIPS compliance, 
rather than on internal knowledge generated through R&D. In addition, during the transitional-
TRIPS period, Indian firms would likely have had limited access to high-quality external 
knowledge9. 
However, the historical development of the Indian pharmaceutical industry complicates 
the story. The strong pre-TRIPS focus on generics, reverse engineering, and government 
dependence meant less focus on developing breakthrough drugs, relative to many foreign 
competitors. The Indian pharmaceutical firms’ relatively low investments in R&D may have 
been insufficient for transforming internally-developed knowledge into the types of innovations 
needed to increase exports, especially for higher-value drugs. Indian pharmaceutical firms did 
increase their R&D investments substantially after 1995. Ranbaxy’s R&D spending rose from 
INR 36 crores (~USD 11 million) in 1994-95 to INR 486 crores (~USD 112 million) in 2005. 
Similarly, Dr. Reddy’s Labs’ increased its R&D spending from INR 13 crores (~USD 3 million) 
in 1999 to 437 crores (~USD 101 million) in 2008. However, this spending is still quite low, 
relative to established global pharmaceutical firms (Bedi, Bedi, & Sooch, 2013), and suggests 
that the Indian pharmaceutical industry may have stalled in a consolidation phase, moving slowly 
towards a mature phase in which R&D investments are likely to deliver substantial returns 
(Kumaraswamy et al., 2012).  
                                                 
9 We are grateful to an anonymous reviewer for making this point. 
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A macroeconomic consideration also complicates the interplay between R&D and 
international activities, as the post-TRIPS period is characterized by increased regulatory 
barriers. A global study of 450 new chemical entities approved by the U.S. Food and Drug 
Administration (USFDA) found that substantially fewer drugs were approved during 2005-2010, 
relative to 1996-2004, despite the doubling of R&D expenditure (Grogan, 2011). Given the 
stringent USFDA approval process, Indian firms, with their short-term focus and reverse 
engineering skills, may have made the strategic choice to continue producing generic and 
incrementally-modified drugs, rather than chasing innovations aimed at developing new 
chemical entities. 
Considering the innovation ecosystem, the presence of more foreign multinationals in 
India, post-TRIPS, will have created greater competition for R&D talent (Chatterjee & 
Sahasranamam, 2018), with the lower concentration of such talent in domestic firms potentially 
decreasing their innovative capabilities and subsequent international competitiveness. Stronger 
IP protection also incentivizes individuals to capitalize on their intellectual capital through new 
ventures, rather than within established firms (Autio & Acs, 2010); this is consistent with India’s 
substantial increase in general entrepreneurship rates during the post-TRIPS period 
(Sahasranamam & Sud, 2016). 
Given opportunities for short-term gains, Indian pharmaceutical firms appear to have 
avoided competing with major global rivals on the basis of R&D-led innovations (Abrol, 2004). 
While the industry’s R&D investment increased substantially during 1995-2014, the largest 
growth occurred during 2000-2005, just before, and at the start of, the product-patent regime’s 
coming into effect. Indian firms may have raced to accumulate reverse-engineering-based patents 
before the restrictions of the TRIPS agreement (Haley & Haley, 2012). Post-TRIPS, growth in 
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R&D investments has been much lower (even negative in some years). During the same period, 
however, the number of innovation-driven joint ventures between Indian and western 
pharmaceutical firms increased (Haley & Haley, 2012), suggesting that Indian firms have relied 
more on technology transfer and external knowledge sourced from foreign firms, rather than 
internal R&D. This is consistent with Abrol’s (2004) argument that most Indian pharmaceutical 
firms would likely be junior partners to global firms during the product-patent regime.  
All of this offers directions for future research. First, our propositions can be developed 
into testable hypotheses, using fine-grained measures of international business activity that 
consider both breadth (e.g., accounting for countries from which the export earnings are 
received) and depth (e.g., accounting for the relative importance of each market). It would also 
be interesting to explore the role of knowledge sourcing strategies on higher-commitment, 
equity-based entry modes.  
Second, R&D investments require time to translate into measurable outcomes. A mix of 
qualitative and quantitative methods may be useful for developing an in-depth understanding of 
the effects that process-level improvements from internal R&D have had in Indian 
pharmaceutical firms following the transition to a product-patent regime. Past research suggests 
that high-technology firms tend to rely on internal knowledge for areas in which they already 
have strengths and on external sources to supplement areas of weakness (Dunlap et al., 2016), 
emphasizing the importance of exploring, simultaneously, the process-level changes related to 
internal and external knowledge sourcing. 
Finally, further research is needed to understand the various mechanisms that Indian 
pharmaceutical firms employed to overcome weak institutional support during the transitional-
TRIPS period. Zhao (2006) found that Chinese firms used internal organizations to substitute for 
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inadequate external institutions when conducting R&D. Exploring similar research questions in 
other emerging markets will offer a comparative basis. It would also be interesting to explore 
how changes in the innovation ecosystem have influenced knowledge sourcing strategies in two 
other industries in which Indian firms have earned global recognition: automotive and 
information technology services (Chatterjee & Sahasranamam, 2018).  
To conclude, we develop theoretical arguments regarding the differential effects of the IP 
regime changes of the transitional- and post-TRIPS periods with respect to firm-level knowledge 
sourcing strategies in Indian pharmaceutical firms. Integrating intellectual property arguments 
with contextually-embedded aspects of the innovation ecosystem, we conjecture that TRIPS 
compliance seems to have led these firms to rely more on the market for external knowledge, 
rather than on internal knowledge, in the quest to increase their international activities, especially 
exporting. This implies that the change in the innovation ecosystem created by the IP regime 
shift has had very different effects with respect to internal and external knowledge sourcing 
strategies in this key Indian industry.   
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Figure 1. Indian pharmaceutical exports and imports during transitional-TRIPS (1995-2004) and 
post-TRIPS (2005-2014) periods  
 
Source: Authors’ calculations based on WTO Data: 
http://stat.wto.org/StatisticalProgram/WSDBViewData.aspx?Language=E, accessed on 
22.03.2014 
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Table 1. Summary of quantitative studies on the relationship between exporting and knowledge sourcing in Indian firms 
 
Estimated coefficient (b) [Observed 
significance level (p),Effect size (r)] 
Article 
Industry 
context 
Time  
period 
Modelling 
approach 
Sample 
size (n) 
Number of 
explanatory 
variables (k) 
Internal knowledge 
sourcing (R&D) 
b[p,r] 
External knowledge 
sourcing 
b[p,r] 
Pre-TRIPS 
Lall & Kumar 
(1981) 
Multiple 
industries 
1966-1968 
OLS 
100 2 -0.03[0.04,0.27]  
1976-1978 58 2 -0.04[0.04,0.17]  
Lall (1986) 
Engineering 
1978 OLS 
100 10 -0.25[0.02,0.24] 0.10[0.47,0.08]a 
0.28[0.01,0.26]b 
Chemicals 45 8 0.42[0.00,0.52] 0.08[0.63,0.08]a 
Kumar & 
Siddharthan 
(1994) 
Pharma-
ceuticals 
1987-1990 Tobit 
102 10 0.46[0.86,0.02] 1.58[0.73,0.04]c 
Electrical 
machinery 
75 10 -1.58[0.50,0.08] 1.36[0.01,0.27]c 
Pre-TRIPS to transitional-TRIPS 
Bhaduri & 
Ray (2004) 
Pharma-
ceuticals 1994-1995 Tobit 
71 5 1.69[0.00,0.47] 13.08[0.00,0.34]d 
Electronics 52 6 2.31[0.00,0.51] -6.50[0.32,0.15]d 
Siddharthan & 
Nollen (2004) 
IT 1994-1998 Tobit 117 6  0.58[0.01,0.26]d 
-0.07[0.78,0.03]e 
Transitional-TRIPS 
Chittoor et al. 
(2009) 
Pharma-
ceuticals 
1995-2004 Panel 1104 14 0.24[0.11,0.05] 0.23[0.00,0.10]f 
Jauhari (2007) Electronics 2000-2005 Tobit 116 9 0.00[0.99,0.00] 0.00[0.97,0.00]a 
0.01[0.07,0.18]e 
0.00[0.22,0.12]g 
Transitional-TRIPS to post-TRIPS 
Bhat & 
Narayan 
Chemicals 2001-2007 Tobit 847 14 4.35[0.02,0.08] -4.73[0.02,0.08]a 
0.10[0.65,0.02]e 
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(2009) 
Majumdar 
(2010) 
IT 2001-2006 Panel 138 11 0.70[0.05,0.17]  
Mishra & 
Jaiswal (2012) 
Multiple 
industries 
2000-2008 Panel 264 9 0.28[0.79,0.02] 1.16[0.00,0.26]c 
Tyagi et al. 
(2014) 
Pharma-
ceuticals 
2000-2012 OLS 13 2 0.79[0.00,0.93]  
Post-TRIPS 
Rentala, 
Anand, & 
Shaban (2014) 
Pharma-
ceuticals 
2005-2013 Panel 251 11 -0.00[0.08,0.12] 
(result driven by 
large exporters) 
1.69[0.00,0.38]a 
Pre-TRIPS to post-TRIPS 
Singh (2009) Multiple 
industries 
1990-2005 2SLS 41434 7 1.17[0.00,0.05]  
Franco & 
Sasidharan 
(2010) 
Multiple 
industries 
1994-2006 Panel 22525 10 0.09[0.03,0.02]  
Effect size (r) is calculated as the square root of t2/(t2+(n-k-1), where t is the test statistic for assessing the significance of the estimated coefficient 
(Durlak, 2009). The interpretation of r, per Cohen (1988) and Rosenthal (1996), is: 0.1: small, 0.3: medium, 0.5: large, 0.7: very large. 
Types of external knowledge sourcing: aRoyalties paid, bLicenses, cTechnology imports, dRaw materials imports, eCapital goods imports, 
fInternational technical resources (including capital goods, royalties, know-how, and raw materials), gSpares and stores imports 
 
